4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injections

4D Molecular Therapeutics reported positive 2-year PRISM Phase 2b results showing durable vision maintenance and large reductions in treatment burden with 4D-150.

Key Highlights:

• Phase 2b (n=45) showed consistent BCVA maintenance and CST control through 2 years for single intravitreal 4D-150 dosing.
• Overall cohort had 78% treatment-burden reduction (2.7 mean supplemental injections vs. 12.0 projected with on-label aflibercept).
• Recently diagnosed subgroup (≤6 months) had 87% reduction (1.6 mean supplemental injections vs. 12.0 projected).
• Safety for Phase 3 dose (n=71 combined): well tolerated with 2.8% transient mild IOI within ~28 weeks; no new inflammation or serious ocular events through data cutoff.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.